EPZM News and Press, Epizyme Inc. From 03/01/22

Epizyme, Inc. (EPZM) Q4 2021 Earnings Conference Call March 1, 2022 8:30 AM ET Company Participants Grant Bogle – President and Chief Executive Officer Shefali Agarwal – Executive Vice President, Chief Medical and Development Officer Conference Call Participants Joseph Thome &#x...

Epizyme press release (NASDAQ:EPZM): Q4 GAAP EPS of -$0.49 misses by $0.08. Revenue of $11.6M (+38.1% Y/Y) misses by $8.82M. Revised 2022 Financial Guidance: 2022 total non-GAAP adjusted operating expenses are now expected to be between $160-180 million, compared to the prior guidance of $170...

TAZVERIK® (tazemetostat) Net Product Revenue of $11.6 Million for 4Q 2021; $30.9 Million for FY 2021 $85 Million in Gross Proceeds Raised in January 2022 Public Offering, Combined with Recent Expense Reductions Announced Today, Extends Cash Runway into...

Epizyme (NASDAQ:EPZM) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open. The consensus EPS Estimate is -$0.48 and the consensus Revenue Estimate is $20.42M (+143.1% Y/Y). Over the last 1 year, EPZM has beaten EPS estimates 75% of the time and has beaten re...

Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a...

Shares of biopharmaceutical company Epizyme (NASDAQ: EPZM) rose 32.1% this week, according to data from S&P Global Market Intelligence . The stock, which closed at $1.06 a share last Friday, opened at that same price on Monday before rising to as high as $1.49 a share on Wed...

Are These 3 Under $4 Penny Stocks Worth Watching Today? With another day of trading penny stocks and blue chips off to an interesting start, there is a lot for investors to consider right now. While the market began strong for penny stocks , we quickly witnessed a turnaround by midd...

Gainers: Palisade Bio (NASDAQ:PALI) +23%. Pharming Group (NASDAQ:PHAR) +14%. Entasis Therapeutics (NASDAQ:ETTX) +13%. Epizyme (NASDAQ:EPZM) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Losers: LogicBio Therapeutics (NASDAQ:LOGC) -50%. Pardes Bios...

MDJM (NASDAQ:MDJH) +64%. The OLB Group OLB +25% reports $1.35B in transaction value post CBD Merchants acquisition. Advanced Micro Devices AMD +13% on Q4 results. Xilinx (NASDAQ:XLNX) +12%. Capri Holdings CPRI +12% on Q3 results. IceCure Medical (NASDAQ:ICCM) +11%. Arrival...

One of the steepest decliners in the biotech sector Thursday was Epizyme (NASDAQ: EPZM) . The cancer-focused biotech saw its shares plummet 44% in value that day, on news of a dilutive secondary stock issue. Epizyme announced that it is floating nearly 56.7 million shares of its...